Work

Postmarket Safety Actions for Novel Oncology Drugs Granted FDA’s Accelerated Approval

Year: 2026

Type: article

Abstract: This cross-sectional study examines postmarket safety actions for novel oncology drugs that received accelerated Food and Drug Administration (FDA) approval.

Source: JAMA Network Open

DOI: 10.1001/jamanetworkopen.2025.53764

Authors: Maryam Mooghali, Joshua D. Wallach, Aaron P. Mitchell, Joseph S. Ross, Reshma Ramachandran

Institutions: Yale University, Emory University, Memorial Sloan Kettering Cancer Center, Yale New Haven Health System

Language: English

Topic: Pharmacovigilance and Adverse Drug Reactions

Subfield: Toxicology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,000

Funders: Yale University, Arnold Ventures

OpenAlex ID: W7123908162

FWCI: 22.99

Cites: 5

Cited by: 4

Related to: